1-[(2-Carboxy-3-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[(2-Carboxy-3-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid
• 化学式: C₂₃H₁₆O₆
• 分子量: 388.4
• InChiKey: SMMANLSONJQFJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
  申请人：Seattle Genetics, Inc.

  公开号：US20200246479A1

  公开（公告）日：2020-08-06

  Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.

  提供了新型抗CD228抗体和抗体药物结合物，以及使用这些抗CD228抗体和抗体药物结合物来治疗癌症的方法。
• Salts of avermectins substituted in the 4"-position and having pesticidal properties
  申请人：Pitterna Thomas

  公开号：US20050090458A1

  公开（公告）日：2005-04-28

  A compound of formula wherein X − is an anion; n is 1,2,3 or 4; R 1 is C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl; or C 2 -C 12 alkenyl; R 2 is hydrogen, unsubstituted or substituted C 1 -C 12 alkyl or C 2 -C 12 alkenyl; R 3 is hydrogen, unsubstituted or substituted C 1 -C 12 alkyl, C 3 -C 12 cycloalkyl, C 2 -C 12 alkenyl; or C 2 -C 12 alkynyl; or R 2 and R 3 together are an alkylene or alkenylene bridge; and, where applicable, E/Z isomers, E/Z isomeric mixtures and/or tautomers; with the proviso that RI is not sec-butyl or isopropyl when R 2 is H and R 3 is methyl; and, where applicable, their possible tautomers; a process for the preparation of those compounds and their tautomers and the use thereof; pesticidal compositions in which the active ingredient has been selected from those compounds and their tautomers; and a process for the preparation of those compositions and the use thereof; intermediates, in free form or in salt form, for the preparation of those compounds and, where applicable, their tautomers, in free form or in salt form, are described.

  式中的化合物 式中 X - 是阴离子；n 是 1、2、3 或 4； R 1 是 C 1 -C 12 烷基、C 3 -C 8 环烷基；或 C 2 -C 12 烯基； R 2 是氢、未取代或取代的 C 1 -C 12 烷基或 C 2 -C 12 烯基； R 3 是氢、未取代或取代的 C 1 -C 12 烷基、C 3 -C 12 环烷基、C 2 -C 12 烯基；或 C 2 -C 12 炔基；或 R 2 和 R 3 共同为亚烷基或烯基桥；以及（如适用）E/Z 异构体、E/Z 异构体混合物和/或同分异构体；但 RI 不能为仲丁基或异丙基，当 R 2 2 为 H 且 R 3 在适用情况下，还包括它们可能的同分异构体；制备这些化合物及其同分异构体的工艺及其用途；活性成分选自这些化合物及其同分异构体的农药组合物；制备这些组合物的工艺及其用途；用于制备这些化合物的游离形式或盐形式的中间体，以及在适用情况下，用于制备这些化合物的游离形式或盐形式的同分异构体。
• ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Genmab A/S

  公开号：EP3703757A1

  公开（公告）日：2020-09-09
• METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
  申请人：Genmab A/S

  公开号：EP3768325A1

  公开（公告）日：2021-01-27
• METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-VEGF ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
  申请人：Genmab A/S

  公开号：EP3873533A1

  公开（公告）日：2021-09-08